Pioneering non-invasive diagnostics through breath analysis and volatile organic compound research — bringing early cancer detection closer to clinical reality.
Our aim is to develop a single breath test to diagnose five major gastrointestinal cancers: oesophageal, gastric, pancreatic, liver and colorectal.
Analysing VOCs in exhaled breath as biomarkers for early-stage disease detection across multiple cancer types.
Profiling exhaleed VOC signatures using Thermal Desorption - Gas Chromatography - Time of Flight - Mass Spectrometry
The bespoke ML platform processes GC-MS breath data using molecular network analysis.
Large-scale multicentre trials across NHS trusts, 99% of patients find breath testing easy or very easy.
A novel breath test pathway designed to streamline suspected cancer referrals, minimise unnecessary invasive procedures and alleviate both the financial and operational strain on the NHS.
Biomarkers owned by Imperial College London. Over ten patents filed worldwide.
What an incredible weekend at the Great Exhibition Road Festival it was for the team! Our stand, Breath, Bark & Predict Seizure, was buzzing with curious minds of all ages. So many wonderful people stopped by to learn about epilepsy and try our "Make Your Own Wearable of the Future" activity. The conversations, the questions, the enthusiasm, it was exactly why we do public engagement.
In the House of Lords Grand Committee debate on cancer outcomes, our breath test was cited by the Baroness Warwick of Undercliffe as an example of an innovative diagnostic test that could help GPs triage patients with vague symptoms, with results potentially available within three days.
We hosted Professor Georg Zeller, Professor at the Leiden University Center for Infectious Diseases (LUCID) and Head of the Microbiome Systems Biology Group at Leiden University Medical Center, for a visit to The Hanna Group. The visit included talks and discussion focused on the microbiome elements of our research — spanning early detection, treatment response, and survivorship in oesophagogastric cancer, as well as our work on paediatric lung infections and neurological diseases, alongside a guest presentation and tour of our VOC lab.
